Company Description
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications.
The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
The company was founded in 2001 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Stephen S. Yoder J.D. |
Contact Details
Address: 225 Franklin Street, 26th Floor Boston, Massachusetts 02110 United States | |
| Phone | 857-246-8998 |
| Website | pieris.com |
Stock Details
| Ticker Symbol | PIRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583648 |
| CUSIP Number | 720795103 |
| ISIN Number | US7207951036 |
| Employer ID | 30-0784346 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen S. Yoder J.D. | Chief Executive Officer, President and Director |
| Thomas Bures | Senior Vice President, Chief Financial Officer and Treasurer |
| Maria Kelman | Executive Director of Investor Relations |
| Dr. Shane Olwill Ph.D. | Senior Vice President and Chief Development Officer |
| Prompong Chaikul | Chief Supply Chain Officer |
| Dr. Florian Witte Ph.D. | Vice President and Head of Alliance Management and Early Project Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Apr 18, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 21, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |